What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

REGN Quantitative Stock Analysis June 20, 2023 — 10:07 am EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN).

Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Access our full analysis report here, it’s free. What The Market Is Telling Us Regeneron’s shares are not very volatile and have only had 5 moves greater than 5% over the last year.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has experienced a notable downturn, touching a 52-week low of $666. With a market capitalization of $71.55 billion and a P/E ratio of 15.6x, this ...

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...

Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.